Stock Report: Aegerion Pharmaceuticals Inc. (AEGR) Report Updated: May 20, 2013 | Print This Page

Aegerion Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases. The company focuses on therapeutics to treat severe inherited lipid disorders. Lipids are naturally occurring molecules, such as cholesterol and triglycerides that are transported in the blood. Its lead product, lomitapide has completed pivotal Phase III clinical trial to treat patients with a rare inherited lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The company also plans to develop lomitapide for the treatment of adult patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.